Abstract. Distant metastasis is one of the crucial parameters determining the type of treatment and prognosis of patients. Previous studies discovered important factors involved in multiple steps of metastasis, the precise mechanisms of metastasis still remain to be clarified. To identify genes associated with this complicated biological feature of cancer, we analyzed expression profiles of 16 metastatic brain tumors derived from primary lung adenocarcinoma (ADC) using cDNA microarray representing 23,040 genes. We applied bioinformatic algorithm to compare the expression data of these 16 brain metastatic loci with those of 37 primary NSCLCs including 22 ADCs, and found that metastatic tumor cells has very different characteristics of gene expression patterns from primary ones. Two hundred and forty-four genes that showed significantly different expression levels between the two groups included plasma membrane bounding proteins, cellular antigens, and cytoskeletal proteins that might play important roles in altering cell-cell communication, attachment, and cell motility, and enhance the metastatic ability of cancer cells. Our results provide valuable information for development of predictive markers as well as novel therapeutic target molecules for metastatic brain tumor of ADC of the lung.
Introduction
Distant metastasis is one of crucial steps in tumor development and progression causing difficulty in treatment and resulting in patient death (1, 2) . Since there is no curative therapy for metastatic tumors at present, novel strategies for diagnosis at an earlier stage and better therapies to improve patient survival with metastatic cancer are urgently required. Distant metastasis is considered to occur as multiple-step events which include invasion from a primary site, penetration into blood or lymphatic flow, circulation to reach distant organs, extravasation into a target organ, and re-growth (3, 4) . To clarify this complicated but clinically important metastatic process, many investigators have attempted to identify the molecules of importance in these steps, but precise mechanisms of metastasis still remain largely unknown (5) (6) (7) .
Because microarray technology allows us to analyze expression level of thousands of genes simultaneously, we previously applied this technology to characterize nonsmall cell lung carcinomas (NSCLCs), which include adenocarcinoma (ADC) and squamous cell carcinoma (SCC), and indicated that biological characteristics of each lung cancer like the risk of lymph node metastasis could be predictable by the expression profile of the tumor cells (8) . In addition to the lymph node metastasis, lung cancer is known to show higher rate of brain metastasis; nearly 30% of metastatic brain tumors are derived from primary lung cancer. Lung ADC is generally characterized by the early development of brain metastasis, that is observed even in some cases whose primary tumor is symptom-free (9) . The incidence of brain metastasis, based on autopsy findings, is as high as 50% in patients with ADC (10, 11) . Few patients who develop brain metastasis from any primary tumor survive >2 years from diagnosis of metastasis, and their median survival time is only 2 months (12). Hence, prediction method of brain metastasis and application of such information to prevent the metastasis are very important for improvement of prognosis and quality of life for patients with lung cancer. At present, it is not possible to precisely predict which patients are likely to develop brain metastasis from lung cancers, although a number of biomarkers have been reported to be such predictive factors (13) (14) (15) (16) (17) .
In this study, we focused on expression profile analysis of metastatic brain tumors derived from primary lung ADC and describe the identification of genes differently expressed between primary and metastatic sites. These data should be 
Materials and methods
Patients and tissue samples. Metastatic brain tumors derived from lung ADC and their clinical information were obtained with informed consent from 16 patients who underwent surgery at the Niigata Cancer Center Hospital (Niigata, Japan). Each tumor was diagnosed according to histopathological subtype and grade. pT and pN factors of primary cancer in the lung was determined on the basis of UICC TNM classification as follows: 8 cases to be T1N0, 4 cases to T2N0, and 4 cases to T3N1-3. All samples were immediately frozen and embedded in TissueTek OCT medium (Sakura, Tokyo, Japan) and stored at -80˚C. This study and the use of all clinical materials mentioned were approved by individual institutional ethics committees.
Laser-microbeam microdissection, extraction of RNA, and T7-based RNA amplification. Cancer cells were selectively collected from the preserved samples using laser-microbeam microdissection (LMM) method (18) . Extraction of total RNA and T7-based amplification were performed as described previously (8, 19) . As a control probe, normal human lung poly(A) RNA (BD Biosciences Clontech, Palo Alto, CA, USA) was amplified using the same amplification condition; 2.5-μg aliquots of amplified RNAs (aRNAs) from each cancerous tissue and from the control were reverse transcribed in the presence of Cy5-dCTP and Cy3-dCTP, respectively.
cDNA microarray. cDNAs spotted on the glass slides were prepared by RT-PCR using a unique primer set that corresponded to cDNA sequence of each gene as described previously (8, 20) . The PCR products were spotted on type VII glass-slides (Amersham Biosciences, Uppsala, Sweden) with a Microarray Spotter Generation III (Amersham Biosciences); 4,608 genes were spotted in duplicate on a single slide. We prepared five different sets of slides (a total of 23,040 spots), each of which contained the same 52 housekeeping genes as well as two non-human negative control genes. Hybridization, washing and detection of signals were carried out as described previously (8, (18) (19) (20) (21) . The fluorescence intensities of Cy5 (tumor) and Cy3 (control) for each target spot were adjusted so that the mean Cy3/Cy5 ratio of the 52 housekeeping genes was equal to one. Because the data derived from low signal intensities are less reliable, we determined a cut-off value for signal intensities on each slide and excluded genes from further analysis when both Cy3 and Cy5 dyes gave signal intensities lower than the cut-off.
Cluster analysis of metastatic brain tumors from lung ADC and primary NSCLCs. We applied a hierarchical clustering method (8, 20, 21) to both genes and 53 lung tumors (16 metastatic lung ADC and an independent set of 37 primary sites of NSCLC analyzed previously) (8) . To obtain reproducible clusters for classification of these 53 samples, we selected 4,423 genes for which valid data were obtained in 90% of the experiments, and whose expression ratios varied by standard deviations of >0.8. The analysis was performed using webavailable software ('Cluster' and 'TreeView') written by M. Eisen (http://genome-www5.stanford.edu/MicroArray/SMD/ restech.html). Prior to applying the clustering algorithm, we log-transformed the fluorescence ratio for each spot and then median-centered the data for each sample to remove experimental bias.
Identification of genes differently expressed between primary lung ADC and brain metastasis of lung ADC. We applied a random permutation test to identify genes that were expressed differently between a group of 16 brain metastatic sites of lung ADC and an independent set of 22 primary lung ADC analyzed previously (8) . Mean (μ) and standard (Û) deviations were calculated from the log-transformed relative expression ratios of each gene in primary (p) and metastatic (m) tumors.
To reduce the dimensionality of the number of potent genes that could discriminate between the two classes, we extracted only genes that fulfilled two criteria: a) signal intensities higher than the cut-off level in at least 50% of the cases; b) |Medm-Medp|≥2, where Med indicates the median derived from log-transformed relative expression ratios in primary ADC (p) or metastatic brain tumor from ADC (m). Then we carried out permutation tests to estimate the ability of individual genes to distinguish between the two groups; samples were randomly permutated between the two classes 10,000 times.
Results

Clustering analysis of metastatic lung ADC and primary NSCLC.
To exclude contamination of normal brain cells surrounding metastatic tumor cells, we employed the LMM system and collected almost pure population of tumor cells. To analyze similarities among samples and among genes, we firstly applied two-dimensional hierarchical clustering algorithm using the expression profile data obtained from 16 metastatic brain tumors from ADC and 37 primary NSCLCs. Expression data in Fig. 1A consists of 4,423 genes that passed through the cut-off filter described in Materials and methods. The dendrogram shown at the top of the figure represents similarities between samples and shorter branch indicates higher similarity. In the tumor axis, three major groups corresponding to a group of primary ADC, that of primary SCC including one adenosquamous carcinoma (ASC) and that of metastatic brain tumors from lung ADC were clearly separated by the information of expression profiles. In the magnified view of this cluster analysis (Fig. 1B , gene cluster-1, -2, and -3), identical genes spotted on different positions on glass slides showed very high similarities in the gene cluster, representing reproducibility and reliability of our experimental procedures. In addition, we identified genes whose expression levels were relatively decreased ( Fig. 1A and B, gene cluster-4) or increased ( Fig. 1A and B, gene cluster-5) in metastatic brain tumors. The genes that revealed decreased expression levels in brain metastatic legions comparing to the primary tumors shown as gene cluster-4 in Fig. 1B included SLC9A1, TNFRSF1A, C14ORF1, and MMP24 (MT5-MMP), which were cancer-related genes or whose expression was reported to be down-regulated in several tumor types (22) (23) (24) (25) . SLC9A1, a Na/H exchanger, was previously reported to be down-regulated in various tumor types (22) . TNFRSF1A (TNFR1) is widely known to induce apoptosis through activation of caspase-8 (23) . C14ORF1, that is recently identified as a gene from the genome sequences and is conserved from yeast to mammalians (24) , is considered to encode a membrane protein expressed abundantly in testis as well as various tumors. MMP24 (MT5-MMP) belonging to the membrane-bound matrix metalloproteinase family, was reported to be overexpressed in some histological types of brain tumors, but down-regulated in prostate cancers (25) . The genes in cluster-5 that were overexpressed in metastatic tumor cells contained MGEA5 that was known to be overexpressed in meningioma and also detected in the patients' sera (26) .
Genes showing differential expression between primary lung ADC and brain metastatic foci of lung ADC.
We compared the expression profiles of 22 primary lung ADCs with those of 16 metastatic lung ADCs to brain using a permutation test to select genes that might be applicable for separation of these two groups. As a result 244 genes were listed as candidates that showed the permutational P-value of <0.001. As shown in Fig. 2A , clustering algorithm using the 244 genes clearly separated primary and metastatic lung ADCs. Similar to that in Fig. 1B , identical genes of IGSF4, spotted on different positions on the slide glasses were also placed into the adjacent rows as shown in Fig. 2B , gene cluster-1. The top-ranked 20 genes that revealed the most significant differences in higher or lower expression between the two groups are listed in Table I . The genes included MT2A which was a candidate gene associated with liver metastasis of colon cancer in our previous study (Fig. 2B) (27, 28) . RFX2 known as one of HLA II regulatory factors which drives HLA II genes expression via cis-acting DNA motif was expressed preferably in metastatic tumor cells (Fig. 2B, gene cluster-2) . RFXAP, also known as HLA II regulatory factor by combining with RFXANK and RFX5, was also up-regulated in brain tumors (Fig. 2B, gene cluster-2) . CXCL13, a ligand to chemokine receptors for CCR1, CCR3 and CXCR5, of which ligandreceptor pairs were recently indicated to play a critical role for distant metastasis, was also activated in brain metastasis (Fig. 2B , gene cluster-2) (29).
Discussion
Although recent development of chemotherapy and radiotherapy is so rapid and remarkable, most of cancer patients who have distant metastasis are incurable (11, 12) . A large body of knowledge on genetic and epigenetic alterations occurring in cancers has been accumulated, but we are still unsuccessful in characterizing differences in biological nature of tumors in individual patients such as metastatic ability and the responses to the various treatments. Bernards and Weinberg have suggested that genes associated with metastasis might be already altered even in tumor cells at an early stage (30) . We also observed through clinical evidence that certain types of tumor cells are highly metastatic compared to others. In fact, some patients are diagnosed to have lung cancer through the neurological symptoms caused by metastatic tumors to the brain as in the cases in this study.
On the other hand, patients diagnosed to have locally advanced NSCLCs are threatened by concurrent risk of local, regional and distant metastasis of the disease. Prophylactic cranial irradiation (PCI) is being investigated as treatment to prevent further brain metastasis and improve survival. Until now several studies have shown that PCI decreases the frequency of additional brain metastases in patients with either SCLC or NSCLC and improved survival (11, 31, 32) . Therefore, if we are able to predict a probability of brain metastases, we would be able to predict, for example, the patients who would have a benefit from PCI. In this study, we selected cases with brain metastasis at a relatively earlier pT and/or pN stages of lung cancer. Generally, systemic spread of tumors cells detected as metastatic foci occurs when cancer has progressed and the size of primary tumors becomes relatively large in host organs. Hence, we considered that the brain metastatic cells examined in this study are likely to have a higher metastatic ability and also have a higher affinity for growth in the brain, and that a comparison of the expression profiles of metastatic lung ADC to brain examined in this study with those of surgically-resected primary ADC obtained in our previous study could help to find important key molecules associated with brain metastasis. The distinct gene-expression profiles we observed between primary lung ADCs, primary SCCs and brain metastatic sites from lung ADC (Fig. 1A) clearly suggested that primary ADCs without metastasis and metastatic ADCs have different biological nature. Because we analyzed three histopathological groups of lung tumors, two of which were histologically of the same origin, one can imagine that selection of genes could separate the three tumor types into two groups, one including lung SCC and the other containing both primary and metastatic ADCs of the lung. However, the computational analysis separated very clearly the group of metastatic tumors from primary ADCs. Since we were unable to obtain the primary lung tumor samples corresponding to brain tumors, it is unclear whether the primary tumors of these patients have different expression profiles from their metastatic tumors. However, our results suggest that these 16 metastatic tumors might have similar biological nature represented by similar gene expression profiles. The genes whose expression levels of metastatic tumors are commonly altered comparing to those of primary tumors could be associated with their highly metastatic ability, and may be applied to prediction of higher risk of metastasis and for development of molecular therapy.
When we compared 244 genes that revealed statistically different expression levels between primary lung carcinomas and distant metastatic legions, with those aberrantly expressed in liver metastasis of colon cancer (27, 28) , DAT1, also known as SLC6A3, and MT2A were commonly down-regulated in the two different metastatic sites originated from colon and lung cancers. MT2A encodes metallothionein and is known to be induced by DNA damage and oxidative stress (33) . In nasopharyngeal cancer, MT2A was overexpressed and associated with tumor proliferative activity (34) .
We previously analyzed gene-expression profiles of 25 metastatic lesions from four organs (lung, liver, kidney and bone) using a metastasis model in mice with multiple organ dissemination by intravenous injection of human small cell lung cancer (SCLC) cells (SBC-5). In a previous study, we extracted 435 genes that seemed to reflect the organ specificity of the metastatic cells (18) . A comparison of the mouse model data and the results in this study identified 21 genes including CXCL13, SPTBN1, and MARCKS that were commonly deregulated in various metastatic target organs; MARCKS alters its subcellular localization from plasma membrane to cytoplasm depending on its phosphorylation status and influence to the cell shape (35) . Some extracellular matrix proteins such as COL1A1, ACTA1, and cellular antigens belonging to the Eph and integrin families were reported to be key molecules playing critical roles for malignant phenotype through cDNA microarray analysis of various kinds of cell lines and primary melanomas (36) . RhoC-related proteins, ARHGDIB and ARHGAP5, were also suggested to be associated with metastatic feature of melanomas (6). Table I . Genes differently expressed between brain metastasis site and primary adenocarcinoma. 
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Alteration of expression levels of these genes might affect actomyosin-based cytoskeletal filaments and cell-cell interaction, and enhance cell motility.
In conclusion, we identified dozens of molecules that might be associated with brain metastasis of lung cancer and would provide useful information to comprehensive understanding of lung carcinogenesis. To our knowledge, this is the first genome-wide gene expression analysis of brain metastasis of clinical NSCLCs. The genes or gene products identified might serve as novel diagnostic and predictive markers for disease progression, and for development of new therapeutic approaches that could lead to molecular targetbased chemotherapy and prevention of metastasis.
